La Jolla Pharmaceutical (NASDAQ:LJPC) saw unusually large options trading on Friday. Stock traders purchased 1,676 put options on the stock. This is an increase of Infinity compared to the average volume of 0 put options.
A number of hedge funds have recently modified their holdings of LJPC. Legal & General Group Plc increased its holdings in shares of La Jolla Pharmaceutical by 11.6% during the second quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 462 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of La Jolla Pharmaceutical during the third quarter valued at approximately $200,000. Trexquant Investment LP bought a new stake in shares of La Jolla Pharmaceutical during the third quarter valued at approximately $217,000. Voya Investment Management LLC bought a new stake in shares of La Jolla Pharmaceutical during the second quarter valued at approximately $243,000. Finally, American International Group Inc. increased its holdings in shares of La Jolla Pharmaceutical by 7.1% during the first quarter. American International Group Inc. now owns 8,571 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 568 shares in the last quarter.
Several analysts have recently issued reports on the company. ValuEngine lowered La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Zacks Investment Research raised La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research note on Wednesday, November 1st. Cowen reissued a “buy” rating and set a $55.00 price target on shares of La Jolla Pharmaceutical in a research note on Friday, October 27th. Jefferies Group reissued a “buy” rating and set a $40.00 price target on shares of La Jolla Pharmaceutical in a research note on Tuesday, October 3rd. Finally, J P Morgan Chase & Co initiated coverage on La Jolla Pharmaceutical in a research note on Wednesday, August 30th. They set an “overweight” rating and a $36.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. La Jolla Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $52.00.
Shares of La Jolla Pharmaceutical (NASDAQ:LJPC) traded up $1.24 on Thursday, hitting $32.07. The stock had a trading volume of 240,881 shares, compared to its average volume of 438,903. La Jolla Pharmaceutical has a 52 week low of $16.41 and a 52 week high of $39.28.
La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.05. research analysts predict that La Jolla Pharmaceutical will post -4.93 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thelincolnianonline.com/2017/12/07/investors-buy-high-volume-of-put-options-on-la-jolla-pharmaceutical-ljpc-updated-updated.html.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.